|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 31/7072 | (2013.01) |
| C07H 19/06 | (2006.01) | ||
| C07H 19/16 | (2006.01) | ||
| A61K 31/7068 | (2013.01) | ||
| C07H 19/00 | (2013.01) | ||
| C07H 19/14 | (2006.01) | ||
| C07H 19/16 | (2013.01) | ||
| A61K 31/7064 | (2006.01) | ||
| A61K 31/7076 | (2006.01) | ||
| C07H 19/14 | (2013.01) | ||
| A61P 31/12 | (2006.01) | ||
| C07H 19/06 | (2013.01) | ||
| C07H 19/04 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| C07H 19/048 | (2006.01) | ||
| A61P 31/16 | (2018.01) | ||
| A61K 31/7068 | (2006.01) | ||
| A61P 31/04 | (2018.01) | ||
| A61K 31/7072 | (2006.01) | ||
| A61P 43/00 | (2018.01) | ||
| C07H 19/00 | (2006.01) | ||
| A61P 1/16 | (2018.01) | ||
| A61P 1/16 | (2006.01) | ||
| A61P 31/14 | (2018.01) | ||
| A61P 31/00 | (2006.01) | ||
| A61P 31/12 | (2018.01) | ||
| A61P 31/04 | (2006.01) | ||
| Y02A 50/30 | (2018.01) | ||
| A61P 31/14 | (2006.01) | ||
| A61P 31/00 | (2018.01) | ||
| C07H 19/04 | (2013.01) | ||
| A61P 31/16 | (2006.01) | ||
| C07H 19/048 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 43/00 | (2006.01) |
| (11) | Patento numeris | 3521297 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 19160413.1 |
| Europos patento paraiškos padavimo data | 2004-04-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-08-07 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-12-22 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 47436803 P | 2003-05-30 | US |
| (72) |
CLARK, Jeremy , US
|
| (73) |
Gilead Pharmasset LLC ,
c/o Gilead Sciences, Inc.
333 Lakeside Drive, Foster City, CA 94404,
US
|
| (54) | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES |
| MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES |